Neurocrine Biosciences(NBIX)

• Single blockbuster product (INGREZZA) generating $1.7B in Part D spending with peak lifecycle status and patent protection until 2040, providing revenue stability.
• Aggressive pipeline expansion with 50 active trials across 20 Phase 3 programs and 22 Phase 2 programs in high-value areas (psychiatric disorders, rare endocrine diseases, movement disorders).
• Strong financial momentum: 27% YoY revenue growth (FY2025 vs FY2024) with $250M net income and 22% YoY R&D spending increase, signaling sustained investment capacity.

Generated by Claude from Neurocrine Biosciences's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

Flagship asset representing 100% of company revenue with 15+ years of patent exclusivity remaining and recent label expansions (Sprinkle formulation, Schizophrenia).